A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB(4) receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis

BACKGROUND: Airway inflammation, mediated in part by LTB(4), contributes to lung destruction in patients with cystic fibrosis (CF). LTB(4)-receptor inhibition may reduce airway inflammation. We report the results of a randomized, double-blind, placebo-controlled study of the efficacy and safety of t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cyst Fibros
Main Authors: Konstan, MW, Döring, G, Heltshe, SL, Lands, LC, Hilliard, KA, Koker, P, Bhattacharya, S, Staab, A, Hamilton, A
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4755340/
https://ncbi.nlm.nih.gov/pubmed/24440167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcf.2013.12.009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados